Free Trial

COMPASS Pathways (CMPS) Stock Forecast & Price Target

$6.97
-0.25 (-3.46%)
(As of 07/12/2024 ET)

COMPASS Pathways - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Consensus Price Target

$47.40
580.06% Upside
High Forecast$120.00
Average Forecast$47.40
Low Forecast$16.00
TypeCurrent Forecast
7/14/23 to 7/13/24
1 Month Ago
6/14/23 to 6/13/24
3 Months Ago
4/15/23 to 4/14/24
1 Year Ago
7/14/22 to 7/14/23
Consensus Rating
Buy
Buy
Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
5 Buy rating(s)
5 Buy rating(s)
5 Buy rating(s)
5 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$47.40$47.40$47.40$47.00
Forecasted Upside580.06% Upside486.55% Upside432.94% Upside353.30% Upside
Get COMPASS Pathways Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for CMPS and its competitors with MarketBeat's FREE daily newsletter.

CMPS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

CMPS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

COMPASS Pathways Stock vs. The Competition

TypeCOMPASS PathwaysMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.71
2.50
Consensus RatingBuyModerate BuyModerate Buy
Predicted Upside580.06% Upside994.26% Upside9.17% Upside
News Sentiment RatingVery Positive News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
6/21/2024Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight
5/13/2024HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$120.00+1,426.72%
4/1/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOverweight$30.00+260.58%
12/12/2023Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$16.00+130.55%
8/22/2023Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$60.00 ➝ $50.00+457.41%
4/12/2023EF Hutton Acquisition Co. I
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy$38.00+277.73%
3/1/2023Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$45.00 ➝ $19.00+131.71%
12/9/2022Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$55.00 ➝ $33.00+226.09%
11/1/2022Loop Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$34.00+222.58%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 11:59 PM ET.

CMPS Forecast - Frequently Asked Questions

What is COMPASS Pathways' forecast for 2024?

According to the research reports of 5 Wall Street equities research analysts, the average twelve-month stock price forecast for COMPASS Pathways is $47.40, with a high forecast of $120.00 and a low forecast of $16.00.

Should I buy or sell COMPASS Pathways stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for COMPASS Pathways in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CMPS shares.

Does COMPASS Pathways's stock price have much upside?

According to analysts, COMPASS Pathways's stock has a predicted upside of 486.55% based on their 12-month stock forecasts.

What analysts cover COMPASS Pathways?

COMPASS Pathways has been rated by research analysts at Cantor Fitzgerald, and HC Wainwright in the past 90 days.

Do Wall Street analysts like COMPASS Pathways more than its competitors?

Analysts like COMPASS Pathways more than other "medical" companies. The consensus rating for COMPASS Pathways is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how CMPS compares to other companies.


This page (NASDAQ:CMPS) was last updated on 7/13/2024 by MarketBeat.com Staff

From Our Partners